Login to Your Account



Other News To Note


Wednesday, August 7, 2013
• KU Leuven, of Belgium, and FIT Biotech Oyj plc, of Tampere, Finland, signed a worldwide license and collaboration agreement to develop immunotherapeutics based on FIT's Gene Transport Unit technology for transient in vivo expression of monoclonal antibodies.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription